Oncology nursing: a clinical reference for nursing students

Cancer affects nearly 2 million Americans each year, and every clinical setting — from the med-surg floor to the ICU — cares for patients undergoing treatment or managing cancer-related complications. Oncology nursing is a specialty requiring deep clinical knowledge: chemotherapy is one of the most hazardous drug classes a nurse will handle, oncologic emergencies can be immediately life-threatening, and cancer pain management demands a sophisticated, individualized approach.

For nursing students, oncology rotations are high-stakes. Errors in chemotherapy administration carry serious consequences. Missing the early signs of tumor lysis syndrome or neutropenic fever can cost a patient their life. This reference covers the core competencies you need for your oncology rotation, NCLEX preparation, and clinical practice: cancer fundamentals, safe chemotherapy administration, oncologic emergencies, pain management, and supportive care.

Use this reference alongside the electrolyte imbalances reference, sepsis nursing reference, nursing lab values cheat sheet, and pharmacology reference.

Quick reference: oncology nursing overview

Cancer fundamentals for nurses

The TNM staging system

Staging communicates the extent of disease and guides treatment decisions. The TNM system is the international standard used for most solid tumors:

• T (tumor): Size and extent of the primary tumor. T0 = no evidence of primary tumor; T1–T4 = increasing size or local invasion; Tis = carcinoma in situ.
• N (nodes): Regional lymph node involvement. N0 = no nodal involvement; N1–N3 = increasing nodal spread.
• M (metastasis): Distant metastasis. M0 = none; M1 = present.

These combine into Stage I–IV: Stage I is localized disease, Stage IV is distant metastasis. Stage groupings affect prognosis, treatment intensity, and goals of care. When a patient’s provider discusses “moving to Stage IV,” understand the clinical implications — the treatment intent often shifts from curative to life-prolonging or palliative.

Cancer grading

Grade describes how abnormal cancer cells look compared to normal cells — a proxy for how aggressively the tumor is likely to behave:

• Grade 1 (well differentiated): Cells look nearly normal; slower growth, better prognosis.
• Grade 2 (moderately differentiated): Intermediate appearance and behavior.
• Grade 3 (poorly differentiated): Cells look very abnormal; more aggressive behavior.
• Grade 4 (undifferentiated/anaplastic): Cells bear little resemblance to normal tissue; most aggressive.

Common cancer types nurses encounter

The cancers most frequently encountered across clinical settings include:

• Lung cancer (most common cancer death in the US): adenocarcinoma and squamous cell (non-small cell) vs small cell — staging and treatment differ significantly.
• Colorectal cancer: frequently presents with bowel obstruction, rectal bleeding, or iron-deficiency anemia.
• Breast cancer: HER2-positive, hormone receptor-positive (ER/PR), and triple-negative subtypes each require different targeted therapies.
• Hematologic malignancies: Leukemia (AML, CLL), lymphoma (Hodgkin’s, non-Hodgkin’s), and multiple myeloma — high risk for oncologic emergencies, particularly neutropenic fever and tumor lysis syndrome.
• Prostate cancer: Most common cancer in men; frequently managed on hormonal therapy as an outpatient.

Chemotherapy nursing care

Safe handling of hazardous drugs

Chemotherapy drugs are classified as hazardous drugs by NIOSH (National Institute for Occupational Safety and Health). Exposure occurs via dermal absorption, inhalation of aerosolized particles, and accidental splashes. Long-term exposure without adequate PPE has been linked to reproductive toxicity, genotoxic effects, and increased cancer risk in healthcare workers. USP <800> sets the regulatory framework for safe handling.

Mandatory PPE for chemotherapy administration:

• Gloves: Double pair of chemotherapy-tested, ASTM D6978-compliant gloves. Change every 30 minutes or immediately if torn or contaminated.
• Gown: Impermeable, lint-free, disposable gown with back closure and closed cuffs. Not a standard lab coat or isolation gown.
• Eye and face protection: Required when there is any splash risk — priming lines, connecting/disconnecting IV tubing, handling oral chemotherapy.
• Respirator: NIOSH-certified N95 or N100 fit-tested respirator if powder or aerosol generation is possible. A surgical mask is not adequate.

Before administration — your verification checklist:

1. Two-nurse independent double-check of drug, dose, route, and patient identity (five rights plus weight-based dose calculation verification).
2. Confirm the patient has signed informed consent for the chemotherapy regimen.
3. Verify pre-medications have been administered per protocol (antiemetics, corticosteroids, diphenhydramine as applicable).
4. Assess IV access: patency, placement, and appropriateness for the specific agent (vesicants require central access or confirmed patent peripheral IV with careful monitoring).
5. Review current labs: CBC with differential (especially ANC), comprehensive metabolic panel, and any agent-specific monitoring (e.g., creatinine clearance for nephrotoxic agents).

Administration routes

Chemotherapy side effects and nursing interventions

Oncologic emergencies

Six oncologic emergencies require immediate nursing recognition. Each has a distinct clinical signature, and early intervention dramatically changes outcomes.

1. Tumor lysis syndrome (TLS)

Tumor lysis syndrome occurs when massive tumor cell death releases intracellular contents into the bloodstream faster than the kidneys can clear them. It is most common with rapidly proliferating hematologic malignancies (Burkitt lymphoma, AML, ALL) and after initiation of chemotherapy or radiation.

The classic electrolyte pattern — remember KPHH:

• K↑ Hyperkalemia — released from lysed cells; cardiac arrhythmia risk
• P↑ Hyperphosphatemia — calcium binds phosphate, driving hypocalcemia
• H↓ Hypocalcemia — secondary to hyperphosphatemia; seizures, tetany, Chvostek/Trousseau signs
• H↑ Hyperuricemia — purine breakdown products; precipitates in renal tubules → acute kidney injury

Nursing priorities:

• Aggressive IV hydration (150–200 mL/hour) to maintain urine output ≥100 mL/hour
• Continuous cardiac monitoring for hyperkalemia-related arrhythmias
• Monitor electrolytes and uric acid every 4–6 hours in high-risk patients
• Administer allopurinol (prophylaxis) or rasburicase (treatment/high-risk) per order
• Do NOT administer potassium-containing IV fluids; avoid calcium unless symptomatic hypocalcemia is confirmed
• Monitor for signs of AKI — rising creatinine, decreased urine output

See the electrolyte imbalances reference for detailed management of hyperkalemia and hypocalcemia.

2. Superior vena cava syndrome (SVCS)

SVCS occurs when a tumor (most commonly lung cancer or lymphoma) compresses or obstructs the superior vena cava, impairing venous return from the head, neck, and upper extremities.

Signs and symptoms: Progressive facial, neck, and upper extremity edema; facial plethora (redness/purplish discoloration); distended neck veins (JVD); dyspnea; headache that worsens when bending forward or lying down; altered mental status in severe cases.

Nursing priorities:

• Elevate head of bed to 45 degrees minimum to reduce venous congestion
• Do NOT obtain IV access in upper extremities — use lower extremity or femoral access only
• No blood pressure measurements on upper extremities
• Prepare patient for urgent imaging (CT of chest) and potential emergent radiation or stenting
• Administer corticosteroids and diuretics as ordered to reduce edema
• Closely monitor respiratory status — airway compromise is the life-threatening risk

3. Neutropenic fever

Neutropenic fever (febrile neutropenia) is defined as:

• Temperature ≥38.3°C (101°F) on a single measurement, or ≥38°C (100.4°F) sustained for one hour
• Absolute neutrophil count (ANC) <500/mm³, or ANC <1,000/mm³ with anticipated decline to <500

ANC calculation: ANC = Total WBC × (% neutrophils + % bands) ÷ 100

Neutropenic fever is a medical emergency — the risk of bacterial sepsis and death is high in immunocompromised patients who may mount minimal inflammatory response.

Nursing priorities:

• Antibiotics must be administered within 60 minutes of fever recognition — do not delay for culture results
• Blood cultures (×2 sets, from different sites) before antibiotics if it does not delay treatment
• Strict neutropenic precautions: private room, visitor restrictions, HEPA filtration if available
• No fresh flowers, fresh fruits/vegetables with skin, or live plants in the room
• Meticulous hand hygiene — the highest-yield intervention for preventing infection in neutropenic patients
• Avoid rectal temperatures, suppositories, and any procedures that break mucosal barriers
• Monitor vital signs frequently — the immunocompromised patient may not mount a fever even with serious infection

For sepsis management in the neutropenic patient, see the sepsis nursing reference.

4. Hypercalcemia of malignancy

Hypercalcemia (serum calcium >10.5 mg/dL corrected for albumin) occurs in 10–20% of cancer patients, most commonly with multiple myeloma, breast cancer, lung cancer, and renal cell carcinoma. The primary mechanism is tumor secretion of parathyroid hormone-related protein (PTHrP), which drives bone resorption.

Signs and symptoms follow the mnemonic “bones, stones, groans, and psychic moans”:

• Bones: bone pain, pathologic fractures
• Stones: kidney stones, polyuria, polydipsia
• Groans: nausea, vomiting, constipation, anorexia
• Psychic moans: confusion, lethargy, altered mental status, coma in severe cases

Nursing priorities:

• IV hydration with normal saline is the first-line treatment — promotes renal calcium excretion
• Bisphosphonates (pamidronate, zoledronic acid) administered IV — onset 24–48 hours, peak effect 4–7 days
• Monitor for cardiac arrhythmias on continuous telemetry — hypercalcemia shortens the QT interval
• Loop diuretics (furosemide) may be added after adequate volume repletion
• Monitor calcium, phosphate, magnesium, and creatinine closely

5. Malignant spinal cord compression

Epidural spinal cord compression occurs in approximately 5% of cancer patients, most commonly from vertebral metastases in lung, breast, prostate, or multiple myeloma. It is a neurological emergency — delays in treatment result in permanent paralysis.

Early warning signs (hours to days before paralysis):

• New or worsening back pain, often with a radicular component
• Pain that worsens with Valsalva, coughing, or lying flat
• Lower extremity weakness, decreased sensation, or ataxia

Late signs (neurological emergency — immediate action required):

• Urinary retention or incontinence (bladder dysfunction is often the presenting symptom)
• Bowel incontinence or constipation
• Paraplegia or paraparesis

Nursing priorities:

• Log roll precautions for all position changes — spinal stability unknown until imaging completed
• Report new back pain with neurological symptoms to provider immediately; urgent MRI is the diagnostic standard
• Administer high-dose corticosteroids (dexamethasone) as ordered — reduces edema around the cord
• Catheterize for urinary retention as ordered; monitor urine output
• Document baseline neurological exam and reassess frequently

6. Sepsis in the immunocompromised patient

Cancer patients — especially those on active chemotherapy — have severely impaired immune responses. See neutropenic fever above for the neutropenia-specific presentation. Key differences from sepsis in the general population: these patients may not mount a fever; tachycardia may be the only initial sign; source identification is critical; empiric broad-spectrum antibiotics covering gram-negative organisms (including Pseudomonas) are started immediately.

Refer to the sepsis nursing reference for full bundle management.

Cancer pain management

Pain affects 55–95% of cancer patients depending on stage and treatment phase. Undertreated cancer pain is associated with impaired quality of life, depression, insomnia, and reduced treatment adherence. Effective pain management is a core nursing competency.

The WHO analgesic ladder

The World Health Organization three-step analgesic ladder provides the framework for cancer pain pharmacotherapy:

• Step 1 — Mild pain (1–3/10): Non-opioid analgesics: acetaminophen, NSAIDs ± adjuvants (antidepressants, anticonvulsants, corticosteroids).
• Step 2 — Moderate pain (4–6/10): Weak or low-dose opioids (codeine, tramadol, or low-dose oxycodone/hydrocodone) ± non-opioids ± adjuvants.
• Step 3 — Severe pain (7–10/10): Strong opioids (morphine, oxycodone, hydromorphone, fentanyl, methadone) ± non-opioids ± adjuvants. No ceiling dose for opioids in cancer pain.

Core principles: Administer analgesics by the clock (scheduled, not PRN), by the mouth (oral route preferred), and by the ladder (titrate up as needed). The goal is to prevent pain, not chase it.

Opioid management in cancer

Opioids are the foundation of moderate-to-severe cancer pain management. Key nursing responsibilities:

• Scheduled (around-the-clock) dosing is preferred over PRN dosing for persistent pain. PRN-only orders are inadequate for continuous cancer pain.
• Breakthrough pain dosing: A rescue dose of an immediate-release opioid is typically prescribed at 10–15% of the total 24-hour opioid dose, available every 1–2 hours as needed. If a patient requires more than 2–4 breakthrough doses per day consistently, notify the provider — the scheduled dose likely needs titration.
• Equianalgesic dosing: When rotating opioids or changing routes, equianalgesic tables are used. Reduce the calculated dose by 25–50% for incomplete cross-tolerance.
• Monitor for opioid side effects: Constipation (universal — begin bowel regimen with all opioids; do not wait for constipation to develop), nausea, sedation, respiratory depression (rate <12, SpO2 drop — have naloxone available per protocol).
• Opioid-induced respiratory depression: Administer naloxone 0.4 mg diluted in 10 mL NS; give 1–2 mL (0.04–0.08 mg) every 2–3 minutes until respiratory rate improves. Avoid full reversal — it precipitates acute pain crisis and withdrawal.

Adjuvant medications

Adjuvants enhance opioid efficacy or target specific pain mechanisms:

• Neuropathic pain (burning, shooting, electric): gabapentin, pregabalin, duloxetine, tricyclic antidepressants.
• Bone pain from metastases: NSAIDs, corticosteroids, bisphosphonates (zoledronic acid), RANK-L inhibitor (denosumab).
• Inflammatory pain: corticosteroids, NSAIDs.
• Muscle spasm: baclofen, cyclobenzaprine.

Non-pharmacological approaches

Complementary pain management does not replace opioids in cancer but reduces total medication burden and improves patient experience. Evidence-based approaches include: heat and cold therapy, positioning and repositioning, therapeutic massage, guided imagery and relaxation techniques, TENS (transcutaneous electrical nerve stimulation), and psychological interventions including cognitive behavioral therapy for pain catastrophizing.

See the drug classifications reference for opioid pharmacology and the pharmacology reference for analgesic drug interactions.

Supportive care and symptom management

Chemotherapy-induced nausea and vomiting (CINV)

Nausea and vomiting are ranked by patients as among the most feared and distressing side effects. Modern antiemetic regimens have substantially improved control but require nursing attention to protocol adherence.

Classification by emetogenic risk: Cisplatin and doxorubicin/cyclophosphamide combinations are highly emetogenic (>90% risk without prophylaxis). Carboplatin and oxaliplatin are moderately emetogenic. Vinca alkaloids and targeted agents vary.

Standard antiemetic regimen for highly emetogenic chemotherapy: Serotonin (5-HT3) antagonist (ondansetron, granisetron) + neurokinin-1 (NK1) antagonist (aprepitant) + dexamethasone, given before chemotherapy and continuing for 2–4 days.

Nursing management: Ensure antiemetics are administered before chemotherapy begins — not after nausea starts. Small frequent meals. Avoid strong food odors. Monitor for dehydration from protracted vomiting; IV fluid replacement may be needed. Distinguish acute CINV (within 24 hours) from delayed CINV (day 2–5) — delayed CINV is frequently under-treated because patients are discharged.

Oral mucositis

Mucositis results from chemotherapy- and radiation-induced damage to the rapidly dividing cells of the oral mucosa. Graded on a 0–4 scale from erythema to inability to eat.

Nursing care:

• Oral assessment at every nursing shift using a validated tool (WHO or OMAS scale)
• Saline and sodium bicarbonate rinses (1 teaspoon each in 8 oz water) four times daily
• Soft-bristle toothbrush; electric toothbrush is acceptable if used gently
• Avoid alcohol-based mouthwashes, commercial mouthwashes with strong ingredients, hot or acidic foods
• For Grade 3–4 mucositis (unable to eat, requires IV nutrition/hydration): pain management with topical anesthetics or systemic opioids; nutritional consultation; IV fluids

Cancer-related fatigue

Cancer-related fatigue (CRF) is the most common symptom reported by cancer patients — distinct from normal tiredness in that it is not relieved by rest, disproportionate to recent activity, and often described as “bone-tired” or “heavy.” Contributing factors include anemia, depression, sleep disturbance, nutritional deficits, and disease itself.

Nursing interventions: Energy conservation (prioritizing activities, pacing); structured aerobic exercise if tolerated (the most evidence-supported intervention for CRF); sleep hygiene education; treat underlying anemia per order (erythropoiesis-stimulating agents, transfusion per facility protocol); screen for and address depression and anxiety.

Nutritional support

Malnutrition affects 40–80% of cancer patients and is associated with worse treatment tolerance, increased infection risk, and reduced survival. Causes include anorexia (cytokine-mediated), mucositis, nausea, taste changes, and tumor-related metabolic alterations.

Nursing priorities: Daily weight; calorie count if nutritional status is declining; early dietitian referral; oral supplementation (high-calorie, high-protein supplements); consider enteral nutrition (tube feeding) if oral intake is insufficient and gut is functional; parenteral nutrition is reserved for patients with non-functional GI tracts.

Psychosocial support

A cancer diagnosis is a life-altering event. Depression and anxiety affect 25–50% of cancer patients. Nurses play a central role in psychosocial care through consistent therapeutic communication, distress screening (NCCN Distress Thermometer), and appropriate referrals.

Refer patients to: oncology social workers, psychiatry/psychology, cancer support groups, chaplaincy services, and palliative care teams for complex psychosocial distress.

Radiation therapy nursing care

Radiation therapy uses high-energy rays to damage cancer cell DNA, preventing replication. It may be curative, adjuvant (post-surgery), or palliative (symptom control). Side effects are site-specific — thoracic radiation causes esophagitis, pelvic radiation causes cystitis and diarrhea, brain radiation causes fatigue and cognitive effects.

Skin care during radiation

Radiation dermatitis progresses from mild erythema to moist desquamation in some patients. Nursing education should include:

• Wash the treatment field gently with mild, unscented soap and lukewarm water
• Pat dry — never rub
• Avoid tight clothing over the treatment field
• No heating pads, ice packs, or temperature extremes to the treatment site
• Use only radiation oncology–approved skin products in the treatment field — not standard lotions, deodorants, or perfumes
• Do not remove skin markings (used to guide radiation alignment)

Radiation safety

External beam radiation is not a contamination risk — patients receiving external beam radiation are not radioactive. Internal radiation (brachytherapy, radioactive iodine I-131) requires different precautions:

• Brachytherapy implants: Time, distance, shielding principles apply; limit visitor time, maintain distance, no pregnant visitors or children
• I-131 (thyroid cancer treatment): Patient isolation; radiation precautions for body fluids (urine especially); specific discharge criteria per radiation safety officer

Managing radiation-specific side effects

• Radiation esophagitis: Soft, cool diet; viscous lidocaine rinse before meals; proton pump inhibitor; nutritional support
• Radiation cystitis: Encourage fluid intake; urinary analgesics (phenazopyridine) for dysuria; monitor for hematuria
• Radiation pneumonitis: Monitor for dyspnea, cough, fever 4–12 weeks post-thoracic radiation; treat with corticosteroids per order
• Radiation mucositis (head/neck): Same care as chemotherapy-induced mucositis, often more severe with combined chemoradiation

Palliative and end-of-life considerations

Palliative care is not synonymous with end-of-life care — it is appropriate alongside curative treatment at any stage of cancer. The goal is relief of suffering, optimization of quality of life, and support for patients and families.

Hospice and transition to comfort-focused care

Hospice is appropriate when a patient’s prognosis is six months or less if the disease follows its expected course and the patient (and family) elects comfort-focused care over life-prolonging treatment. Nurses are often central to identifying when a goals-of-care conversation is needed: patient expressing fatigue with treatment, repeated hospitalizations, worsening functional status, or expressed wish to focus on quality rather than quantity of life.

Nursing role in goals-of-care conversations: Create privacy, ensure the right people are present (patient, family, the team), listen as much as you speak, and avoid medical jargon. Document patient’s stated preferences for life-sustaining treatment (CPR, mechanical ventilation, artificial nutrition) in the medical record and ensure advance directives are current.

Comfort measures at end of life

• Pain management: Opioids remain appropriate and are the standard of care. The Principle of Double Effect supports opioid use for comfort even if there is a theoretical secondary effect on respiration — comfort is the goal, and adequate pain control is not euthanasia.
• Dyspnea management: Low-dose opioids are effective for terminal dyspnea. Fan directed at the face reduces perceived air hunger. Anxiolytics for associated anxiety. Avoid supplemental oxygen if the patient does not have hypoxemia — evidence does not support routine use.
• Terminal secretions (“death rattle”): Repositioning, suctioning only if accessible, glycopyrrolate or hyoscine to reduce secretions; reassure family that the patient is not choking.
• Symptom clusters: Delirium, agitation, and pain often co-occur at end of life. Haloperidol is first-line for terminal delirium; midazolam may be added for refractory agitation.

Related references

This article is one resource within a broader clinical library. For related topics:

• Sepsis nursing reference — full Sepsis-3 criteria, qSOFA, and the 1-hour SEP-1 bundle for managing sepsis in oncology patients
• Electrolyte imbalances reference — detailed management of hyperkalemia, hypocalcemia, and hyperphosphatemia in tumor lysis syndrome
• Nursing lab values cheat sheet — CBC interpretation, ANC calculation, and comprehensive metabolic panel values
• Drug classifications reference — opioid pharmacology, antiemetics, and chemotherapy drug classes
• Pharmacology reference — analgesic dosing, drug interactions, and medication safety
• Vital signs reference — normal ranges and hemodynamic assessment for unstable oncology patients